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Abstract
Background: Bone loss with aging and menopause increases the risk of fragile vertebral fracture, osteoporotic
vertebral compression fracture (OVCF). The fracture causes severe pain, impedes respiratory function, lower the
quality of life, and increases the risk of new fractures and deaths. Various medications have been prescribed to
prevent a secondary fracture, but few study summarized their effects. Therefore, we investigated their effects on
preventing subsequent OVCF via meta-analyses of randomized controlled trials.
Methods: Electronic databases, including MEDLINE, EMBASE, CENTRAL, and Web of Science were searched for
published randomized controlled trials from June 2015 to June 2019. The trials that recruited participants with at
least one OVCF were included. We assessed the risk of bias of every study, estimated relative risk ratio of secondary
OVCF, non-vertebral fracture, gastrointestinal complaints and discontinuation due to adverse events. Finally, we
evaluated the quality of evidence.
Results: Forty-one articles were included. Moderate to high quality evidence proved the effectiveness of zoledronate
(Relative Risk, RR: 0.34; 95% CI, 0.17–0.69, p= 0.003), alendronate (RR: 0.54; 95% CI: 0.43–0.68; p < 0.0001), risedronate (RR:
0.61; 95% CI: 0.51–0.73; p< 0.0001), etidronate (RR, 0.50; 95% CI, 0.29–0.87, p < 0.01), ibandronate (RR: 0.52; 95% CI: 0.38–0.71;
p < 0.0001), parathyroid hormone (RR: 0.31; 95% CI: 0.23–0.41; p< 0.0001), denosumab (RR, 0.41; 95% CI, 0.29–0.57; p<
0.0001) and selective estrogen receptor modulators (Raloxifene, RR: 0.58; 95% CI: 0.44–0.76; p < 0.0001; Bazedoxifene, RR:
0.66; 95% CI: 0.53–0.82; p = 0.0002) in preventing secondary fractures. Moderate quality evidence proved romosozumab
had better effect than alendronate (Romosozumab vs. alendronate, RR: 0.64; 95% CI: 0.49–0.84; p = 0.001) and high quality
evidence proved that teriparatide had better effect than risedronate (risedronate vs. teriparatide, RR: 1.98; 95% CI: 1.44–2.70;
p < 0.0001).
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Conclusion: Zoledronate, alendronate, risedronate, etidronate, ibandronate, parathyroid hormone, denosumab
and selective estrogen receptor modulators had significant secondary prevention effects on OVCF. Moderate
quality evidence proved romosozumab had better effect than alendronate. High quality evidence proved PTH
had better effect than risedronate, but with higher risk of adverse events.
Keywords: Secondary prevention, Conservative treatment, Osteoporosis, Meta-analysis, Osteoporotic fracture, Senior
Background
Osteoporotic vertebral compression fracture (OVCF) is
one of the most common fragile fractures, with a preva-
lence of 30 to 50% in people over 50 years of age [1]. It
causes severe pain and disability, raises the risk of sec-
ondary fracture more than 4-fold [2, 3], and increases
the risk of mortality [4]. Therefore, secondary prevention
of OVCF was critical and should be emphasized to im-
prove patients’ quality of life. However, though the pri-
mary prevention efficacy of medications have been well
summarized [5–10], only one systematic review targeted
on their secondary prevention effects [11]. Therefore, to
investigate the efficacy of current medication therapies
on preventing secondary OVCF, we conducted this study
through systematically literature review and meta-ana-
lyses of randomized controlled trials (RCTs).
Methods
Search for studies
Four major electronic databases (MEDLINE, EMBASE,
CENTRAL, andWeb of Science) were searched with a devel-
oped search strategy that consisted of keywords “controlled
trials”, “osteoporotic fracture”, “bisphosphonate”, “parathy-
roid hormone”, “denosumab” “calcitonin”, “Raloxifene”,
“Bazedoxifene” “hormone replacement”, “romosozumab”,
“abaloparatide”, etc., and others (Additional file 1). The
search spanned the period from June 2015 to June 2019, with
weekly alerts of updated published trials. Reference lists from
other reviews and studies were also checked for relevant arti-
cles. The references were managed with Endnote X7 (Clari-
vate Analytics).
Selection of studies
Three authors (YZJ, BX, and MJC) independently
screened the titles and abstracts of studies and evaluated
their relevance to our study. A study was included if it
involved patients with osteoporosis. A subsequent full-
text assessment was done by three authors (YZJ, BX,
and JHL) independently. Randomized controlled trials
(RCTs) published in English that investigated the effi-
cacy of currently approved medications for patients with
OVCF were included. The studies that included osteo-
porosis patients without distinguishing their fracture his-
tory were included if the data of the participants with
prevalent fractures was adequately presented. Studies
that recruited patients with traumatic vertebral fracture,
secondary osteoporosis, or did not report results in di-
chotomous data (i.e., patient-years, etc.), were excluded.
The included medications were the approved ones,
including zoledronate, alendronate, risedronate, etidro-
nate, ibandronate, minodronate, pamidronate, calcitonin,
hormone replacement therapy, parathyroid hormone,
denosumab, romosozumab, raloxifene, and bazedoxifene
[12–14]. Post hoc analyzed RCTs were also included,
with taking care of duplicated data input. Disagreements
between reviewers were resolved by discussion or, if un-
resolved, by consultation with consultation with librar-
ians and a statistic professor from SMG-SNU Boramae
Medical Center.
Data extraction and risk of bias
Basic characteristics of each study were independently
extracted by YZJ, BX, and JHL with a designed table that
contains the number of participants, interventions, com-
parisons, and outcomes. The primary outcome of this
study was the vertebral fracture ratio in the final visit,
and the secondary outcomes were gastrointestinal (GI)
complaints of bisphosphonates, discontinuation due to
adverse events (AEs), and non-vertebral fracture ratio.
The risk of bias was measured independently by YZJ,
BX, and JHL with the tool recommended in updated
guidelines of Cochrane Back and Neck Group [15]. The
detection bias was rated for main result (vertebral frac-
ture). The loss ratio was acceptable for a middle- or
long-term trial (observational period > 1 year), if that
was not exceeded 30%. The risk of other sources of bias
was rated as low risk if the article stated both conflict of
interest and sponsor of the trial and no other serious
risk of bias was reported.
Data analysis and quality of evidence
Relative risk (RR) and its 95% confidence intervals (CIs)
were used to estimate the effect of interventions, with p-
values < 0.05 considered significant. The overall effect
size was calculated with a random effects model [15].
Heterogeneity between studies was identified and mea-
sured with p-value and I2 value from Chi-squared test,
p-value < 0.1 was identified as significant, and I2 < 40%
was considered as not important, I2 between 40 and 74%
indicated moderate to substantial, I2 > 75% was identified
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as a considerable magnitude [15]. In studies with
more than two arms, intervention groups were input
into each subgroup and the data in the control
groups were separated equally and then were com-
pared to their counterparts. Sensitivity analyses were
used to explore the interference from a study by ex-
cluding it from syntheses and the impact from loss to
follow-up population by compositing the missing
events according to event ratio in control groups [16].
The data was analyzed by two authors (YZJ and JHL)
with RevMan 5.3.3 (Cochrane).
We evaluated five factors of the results to determine
the quality of evidence, including study limitation, im-
precision, indirectness, inconsistent and publication bias,
followed the GRADE approach. The criteria for down-
regulating the level referred to the handbook of GRADE
and guidelines from Cochrane Back and Neck Group
[15, 16]. In the case that an outcome included one trial
with no unclear or high risk of bias, the study limitation
item was rated as not serious if its result remained same
direction and signficancy with the pooled result.
Results
Characteristics of included studies and risk of bias
A total of 6850 articles were identified. Among them, 631
were subjected to full-text assessment. After full-text
examination, 41 articles were finally included in this study
(Fig. 1). Among them, 34 compared the effects of medica-
tions with control groups. Bisphosphonates (BPs) were
compared in 19 RCTs [17–33, 35, 36], calcitonin in 3 [37–
39], hormone replacement therapy (HRT) in 3 [40–42],
parathyroid hormone (PTH), teriparatide, or abaloparatide
in 5 [43–47], denosumab in 2 [48, 49], and selective estro-
gen receptor modulators (SERMs) in 3 [50–52]. Five trials
compared between the effects of medications, risedronate
vs. etidronate [53], ibandronate vs. risedronate [54], romo-
sozumab vs. alendronate [55], and teriparatide vs. risedro-
nate [57, 58]. Follow-up duration in most trials was 2 to 3
years. Other basic characteristics of included studies were
summarized in Table 1.
Approximately half of the biases were rated as unclear
risk (Additional file 2). Risk of other sources of bias was
rated as high in one study because the criteria used in its
Fig. 1 Flow chart of selected studies
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Table 1 Characteristics of included studies
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Table 1 Characteristics of included studies (Continued)
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Table 1 Characteristics of included studies (Continued)
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two clinical centers were different [21]. Performance bias
was rated as high risk in 6 trials for significantly different
compliance between groups [26, 46, 52] and the open-
label study design used in 4 trials [20, 27, 37, 40].
Fujita et al. treated a teriparatide 1.4 μg/week group
as a placebo group, and therefore, we followed their
grouping and classified their data of teriparatide
1.2 μg/week group as the control group [45]. On the
other side, since the control groups in other studies
all received placebo, which was different from Fujita
et al.’s study, it might affect the final result. There-
fore, we performed a sensitivity analysis about this re-
sult, with excluding the Fujita el al.’s study from the
original analysis and then compared the results from
original analysis and sensitivity analysis (Table 1).
Sorensen et al. reported a 2-year extension trial [23]
of a 3-year original trial [22]. In the entension trial,
the authors treated the initial time point of the exten-
tion trial as baseline. Therefore, while synthesizing
the data, we deemed the data from the two studies
were not duplicated and synthesized the data as from
two studies. However, because the participants in ex-
perimental group and control group in the extension
study had different medication history, the risk of se-
lection bias of the extended trial was rated as high
(Additional file 2).
Table 1 Characteristics of included studies (Continued)
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G2: Ibandronate 1 mg iv
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Hadji, 2012 [57] 710 100% 71 G1: Risedronate: 35 mg/
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PLC Placebo, PTH Parathyroid hormone, ALD Alendronate
aThe study included patients with and without fracture history, and only the data of patients with fracture history was analyzed
bPost hoc analysis of previous data
cData on the third year was pooled because the study design was changed to open-label and all participants in the fourth year received Etidronate
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Table 2 Summary of findings of osteoporotic vertebral fracture and non-vertebral fracture
Comparison RR (95% CI) No. of participants (studies) Quality of the evidence
Vertebral fracture
Antiresorptive medication vs. Control 0.59 (0.53 to 0.65) 21,012 (30 RCTs) –
ZOL vs. Control 0.34 (0.17 to 0.69) 657 (1 RCT) a MODERATE b,
ALN vs. Control 0.54 (0.43 to 0.68) 2277 (3 RCTs) c HIGH
RISE vs. Control 0.61 (0.51 to 0.73) 2645 (5 RCTs) d MODERATE e
Etidronate vs. Control 0.60 (0.39 to 0.92) 618 (7 RCTs) f MODERATE g,
Ibandronate (sufficient) vs. Control 0.52 (0.38 to 0.71) 2929 (1 RCT) h MODERATE i,
Ibandronate (insufficient) vs. Control 0.87 (0.69 to 1.11) 2860 (1 RCT) j MODERATE k
Minodronate vs. Control 0.44 (0.31 to 0.63) 674 (1 RCT) l LOW m
Pamidronate vs. Control 0.33 (0.13 to 0.84) 90 (1 RCT) n VERY LOW o
Calcitonin vs. Control 1.02 (0.14 to 7.36) 157 (3 RCTs) p VERY LOW q
HRT vs. Control 0.86 (0.29 to 2.52) 147 (3 RCTs) r LOW s
PTH vs. Control 0.32 (0.24 to 0.43) 2632 (4 RCTs) t MODERATE u
Denosumab vs. Control 0.41 (0.29 to 0.57) 1654 (2 RCTs) v MODERATE w
RLX vs. Control 0.58 (0.44 to 0.76) 2447 (2 RCTs) x HIGH
BZA vs. Control 0.66 (0.53 to 0.82) 3857 (1 RCT) y MODERATE z
ALN vs. Denosumab 0.69 (0.41 to 1.17) 722 (1 RCT) aa LOW bb
Romosozumab vs. Alendronate 0.64 (0.49 to 0.84) 4093 (1 RCT)cc MODERATEdd
RISE vs. Etidronate 1.12 (0.69 to 1.81) 433 (1 RCT) ee MODERATE ff
Ibandronate vs. RISE 1.01 (0.79 to 1.31) 1228 (1 RCT)gg HIGH
RISE vs. Teriparatide 1.98 (1.44 to 2.70) 2070 (2 RCTs) hh HIGH
HRT vs. Etidronate 0.63 (0.12 to 3.32) 35 (1 RCT) ii VERY LOW jj
Non-vertebral fracture
ZOL vs. Control 0.54 (0.32 to 0.91) 661 (1 RCT)kk –
ALN vs. Control 0.81 (0.65 to 1.01) 2027 (1 RCT)ll –
RISE vs. Control 0.71 (0.54 to 0.92) 2836 (4 RCTs)mm –
Etidronate vs. Control 0.95 (0.59 to 1.53) 395 (4 RCTs)nn –
Ibandronate (sufficient) vs. Control 1.10 (0.85 to 1.41) 2929 (1 RCT)oo –
Ibandronate (insufficient) vs. Control (only Hip fracture) 0.59 (0.26 to 1.31) 2860 (1 RCT)pp –
Minodronate vs. Control 0.80 (0.35 to 1.84) 674 (1 RCT)qq –
Pamidronate vs. Control 0.33 (0.04 to 3.10) 100 (1 RCT)rr –
PTH vs. Control 0.53 (0.36 to 0.78) 2454 (3 RCTs)ss –
Denosumab vs. Control 0.45 (0.20 to 1.03) 952 (1 RCT)tt –
Romosozumab vs. ALN 0.74 (0.54 to 1.00) 4093 (1 RCT)uu
ALN vs. Dmab 1.49 (0.52 to 4.24) 722 (1 RCT)vv –
Ibandronate vs. RISE 1.12 (0.75 to 1.66) 1134 (1 RCT)gg –
RISE vs. Teriparatide 1.28 (0.94 to 1.73) 2070 (2 RCTs)ww –
HRT vs. Etidronate 0.94 (0.06 to 13.93) 35 (1 RCT)xx –
RR Relative Risk, ZOL Zoledronate, ALN Alendronate, RISE Risedronate, PTH Pamidronate, RLX Raloxifene, BZA Bazedoxifene, HRT Hormone replace therapy
aNakamura, 2017 [17]
bStudy limitations: the trial included had unclear risk of performance bias
cLiberman, 1995 [20]; Black, 1996 [18]; Kushida, 2004 [19, 53]
dClemmesen, 1997 [21]; Harris, 1999 [25]; Reginster, 2000 [22]; Fogelman, 2000 [24]; Sorensen, 2003 [23]
eStudy limitations: four trials were included, with unclear risk of selection bias, performance bias and attribution bias
fShiota, 2001 [29]; Montessori, 1997 [28]; Lyritis, 1997 [27]; Watts, 1990 [30]; Harris, 1993 [36]; Wimalawansa, 1998 [41]; Guanabens, 2000 [26]
gStudy limitations: seven trials were included, with unclear to high risk of selection bias, attribution bias, other bias, and performance bias
hChesnut, 2004 [31]
iStudy limitations: one trial was included, with unclear risk of performance bias and attribution bias
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Comparison with control group
Antiresorptive medications
The result of antiresorptive medications, including
BPs, HRT, SERMs, calcitonin, and denosumab, were
pooled together to investigate the effects of the medi-
cations. Thirty-three studies involving 21,012 partici-
pants were included. The result indicated that the
administration of antiresorptive medications could sig-
nificantly reduce the risk of the secondary OVCF (RR,
0.59; 95% CI, 0.53–0.65, p < 0.00001) (Table 2, Add-
itional file 3a). Bisphosphonates did not significantly
increase gastrointestinal (GI) complaints (RR, 1.02,
p = 0.45; Additional file 3b). The result was treated as
a secondary outcome because the heterogeneity in the
comparison.
Zoledronate
Moderate quality evidence proved that zoledronate
could significantly decrease the risk of secondary OVCF
(RR, 0.34; 95% CI, 0.17–0.69, p = 0.003; Fig. 2a, Table 2),
without significant increase in discontinuation due to
medication (RR, 1.99; 95% CI, 0.76–5.25, p = 0.16;
Table 3, Additional file 3c). Additionally, zoledronate
could significantly decrease event ratio of non-vertebral
fractures (RR, 0.54; 95% CI, 0.32–0.91; p = 0.02; Table 2,
Additional file 3d).
Alendronate
High quality evidence proved that administrating alendro-
nate significantly reduced the proportion of participants
who had subsequent vertebral fractures (RR, 0.54; 95% CI,
0.43–0.68; p < 0.0001; heterogeneity, p = 0.63, I2 = 0%; Fig.
2b, Table 2). No significant increase in GI complaints or
discontinuation was observed in the alendronate group (GI
complaints, RR, 1.03; 95% CI, 0.93–1.15, p = 0.55; Discon-
tinuation, RR, 0.88; 95% CI, 0.64–1.22, p = 0.46; Table 3,
Additional file 3e and f). Alendronate had no significant ef-
fect on preventing non-vertebral fractures (RR, 0.81; 95%
CI, 0.65–1.01, p = 0.07; Table 2, Additional file 3g).
jRecker, 2004 Recker, 2004 [32]
kOne trial included, with unclear risk of performance bias and other bias
lMatsumoto, 2009 [33]
mOne trial was included, with unclear risk of performance bias, attribution bias and other source of bias. Imprecision: the number of events was 115 and OIS was
not met
nBrumsen, 2002 [35]
oStudy limitation: one trial included, with unclear risk of selection bias. Imprecision (rating down two levels): 20 events and CIs included appreciable benefit
pHodsman, 1997 [38]; Peichl, 1999 [37]; Chesnut, 2005 [39]
qStudy limitation: two trials had unclear to high risk of selection bias, performance bias, attribution bias and other bias. Imprecision (rating down two levels): 15
events and CIs included appreciable benefit and harm
rLufkin, 1992 [42]; Wimalawansa, 1998 [41]; Gutteridge, 2002 [40]
sStudy limitation: two trials had unclear risk of selection bias. Two trials had unclear to high risk of performance bias. Three trials had unclear risk of attribution
bias. Three trials had unclear risk of other bias. Imprecision (rating down two levels): 34 events and CIs included appreciable benefit and harm
tNakamura, 2012 [44], Neer, 2001 [43], Greenspan, 2007, Fujita, 2014 [45]
uOne trial had unclear risk of selection bias, performance bias and attribution bias. One trial had high risk of performance bias
vBoonen, 2011 [49]; Nakamura, 2014 [48]
wStudy limitation: two trials had unclear risk of selection bias and performance bias. One trial had had unclear risk of other bias
xEttinger, 1999 [50], Lufkin, 1998 [51]
yPalacios, 2015 [52]
zStudy limitation: one trial had high risk of performance bias and unclear risk of attribution bias and other bias
aaNakamura, 2014 [48]
bbStudy limitation: one study included, with unclear risk of selection bias, performance bias, and other bias. Imprecision: the number of events was 66, and OIS
was not met
ccSaag, 2017 [55]
ddStudy limitation: one trial was included, with unclear risk of performance bias
eeKushida, 2004 [53]
ffStudy limitation: one trial was included, with unclear risk of selection bias, attribution bias and other bias
ggNakamura, 2013
hhHadji, 2012 [57]; Kendler, 2017 [58]
iiWimalawansa, 1998 [41]
jjStudy limitation: one trial was included, with unclear risk of performance bias, attribution bias and other bias. Imprecision (rating down two levels): few events
and CIs included appreciable benefit and harm
kkNakamura, 2017 [17]
llBlack, 1996 [18]
mmClemmesen, 1997 [21]; Harris, 1999 [25]; Reginster, 2000 [22]; Sorensen, 2003 [23]









wwHadji, 2012 [57]; Kendler, 2017 [58]
xxWimalawansa, 1998 [41]
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Risedronate
Moderate quality evidence indicated that risedronate
had a significant effect on preventing subsequent verte-
bral fractures (RR, 0.61; 95% CI, 0.51–0.73, p < 0.0001;
Fig. 2c, Table 2). Risedronate administration did not sig-
nificantly elevate GI complaints (RR, 1.09; 95% CI, 0.96–
1.23, p = 0.18) or discontinuation rate (RR, 0.88; 95% CI,
0.69–1.12, p = 0.28) (Table 3, Additional file 3h and i).
Risedronate had a significant effect on preventing non-
vertebral fractures (RR, 0.71; 95% CI, 0.54–0.92, p = 0.01;
Table 2, Additional file 3j).
Etidronate
Moderate quality evidence showed that the administra-
tion of etidronate could significantly reduce the risk of
subsequent vertebral fractures (RR, 0.50; 95% CI, 0.29–
0.87, p < 0.01; Fig. 2d, Table 2). The result was consistent
with that of sensitivity test, in which a study [29] with a
small sample size and big variance was excluded
(Additional file 3k). No significant difference was observed
in GI complaints (RR, 0.57; 95% CI, 0.28–1.15, p = 0.12) or
discontinuation (RR, 0.40; 95% CI, 0.03–5.48, p = 0.50)
between intervention and control groups (Table 3, Add-
itional file 3l and m). Etidronate did not have a significant
effect on preventing non-vertebral fractures (RR, 0.95;
95% CI, 0.59–1.53, p = 0.83; Table 2, Additional file 3n).
Ibandronate
Moderate quality evidence proved that ibandronate
administrated 2.5 mg daily or 20 mg intermittently
could significantly reduce the subsequent fracture risk
(RR, 0.52; 95% CI, 0.38–0.71, p < 0.0001; Fig. 2e, Table
2), while insufficient dosages (0.5 mg or 1 mg per 3
months) did not (RR, 0.87; 95% CI, 0.69–1.11,
p = 0.27; Fig. 2f, Table 2). Ibandronate did not signifi-
cantly raise the risk of discontinuation due to adverse
events (sufficient dose: RR, 0.90; 95% CI, 0.69–1.18,
p = 0.45; insufficient dose: RR, 1.27; 95% CI, 0.98–
1.66, p = 0.07) (Additional file 3o and p, Table 3).
Neither sufficient nor insufficient dosage of ibandro-
nate had significant effect on preventing non-vertebral
fractures (sufficient: RR, 1.10; 95% CI, 0.85–1.41,
p = 0.47; insufficient, only hip fracture: RR, 0.59; 95% CI,
0.26–1.31; p = 0.19; Table 2, Additional file 3q and r).
Minodronate
Low quality evidence proved minodronate had signifi-
cant effect in reducing secondary fracture (RR, 0.44; 95%
CI, 0.31–0.63; p < 0.001; Fig. 2g, Table 2). Minodronate
did not have a significant effect on preventing non-verte-
bral fractures (RR, 0.80; 95% CI, 0.35–1.84, p = 0.60;
Table 2, Additional file 3s).
Fig. 2 Forest plot of the secondary prevention effects of bisphosphonates. a Zoledronate; b Alendronate; c Risedronate; d Etidronate; e Ibandronate
(sufficient dose); f Ibandronate (insufficient dose); g Minodronate; h Pamidronate
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Pamidronate
Very low quality evidence indicated significantly lower risk
of secondary fracture due to pamidronate (RR, 0.33; 95%
CI, 0.13–0.84, p = 0.02; Fig. 2h, Table 2). Pamidronate did
not have significant effect on preventing non-vertebral
fractures (RR, 0.33; 95% CI, 0.04–3.10, p = 0.33; Table 2,
Additional file 3t).
Calcitonin
Very low quality evidence proved calcitonin had no sig-
nificant effect on preventing secondary fracture (RR,
1.02; 95% CI, 0.14–7.36, p = 0.98) (Table 2).
HRT
Low quality evidence proved HRT had no significant ef-
fect on prevention of secondary vertebral or non-vertebral
fracture (vertebral: RR, 0.88; p = 0.78; non-vertebral: RR,
0.37; 95% CI, 0.04–3.05, p = 0.36; Table 2, Additional file
3u). HRT did not significantly elevate the risk of discon-
tinuation (RR, 0.53, 95% CI, 0.17–1.61, p = 0.26; Table 3,
Additional file 3v).
Parathyroid (PTH)
Moderate quality evidence proved that the administration
of teriparatide 28.2 μg/week or 56.5 μg/week, abalopara-
tide 80 μg/day, and recombinant human (rh)PTH 20 μg/
day or rhPTH 40 μg/day could significantly reduce the risk
of secondary fracture (Table 2). The synthesized RR was
0.31 (95% CI, 0.23–0.41; p < 0.0001) and the heterogeneity
between different doses was insignificant (p = 0.45, Fig. 3a).
The result of the sensitive analysis that excluded the trial
had teriparatide 1.4 μg/week group as its control group
[45] showed no significant change (RR, 0.31, 95% CI,
0.22–0.44, p < 0.00001). The risk of discontinuation due to
medication was significantly raised by PTH administration
(RR, 1.54; 95% CI, 1.11–2.13, p < 0.009; Additional file
3w). Forty μg/day rhPTH significantly elevated the risk of
discontinuation, while 20 μg/day or 56.5 μg/week did not,
but no significant heterogeneity was observed between
groups. PTH had significant effect on preventing non-ver-
tebral fractures (RR, 0.52; 95% CI, 0.36–0.75; p = 0.0005;
Table 2, Additional file 3x).
Denosumab
Moderate quality evidence proved that the administra-
tion of denosumab significantly reduced the risk of sec-
ondary fracture (RR, 0.41; 95% CI, 0.29–0.57; p < 0.0001;
Fig. 3b, Table 2). No significant increase in discontinu-
ation due to medication was observed (RR, 0.75; 95% CI,
0.44–1.27, p = 0.29; Table 3, Additional file 3y). Denosu-
mab did not have a significant effect on preventing non-
vertebral fractures (RR, 0.45; 95% CI, 0.20–1.03, p = 0.06;
Table 2, Additional file 3z).
SERMs
Both raloxifene (RLX) and bazedoxifene (BZA) could
significantly reduce risk of secondary fracture (RLX: RR,
0.58; 95% CI, 0.44–0.76, p < 0.0001. BZA: RR, 0.66;
95%CI, 0.53–0.82, p = 0.0002; Fig. 3c and d). Heterogen-
eity between 60 μg/day and 120 μg/day of RLX was sig-
nificant and substantial (test for subgroup differences,
p = 0.06, I2 = 72.1%; Fig. 3c). The effect of BZA was
proved by moderate quality evidence and the effect of
RLX was supported by high quality evidence (Table 2).
Comparison between interventions
Comparison between BPs
Moderate quality evidence proved no significant differ-
ence in the effects on preventing vertebral fracture be-
tween risedronate and etidronate (RR, 1.12; 95% CI,
0.69–1.81, p = 0.66; Additional file 4a). High quality
Table 3 Discontinuation due to medication
Comparison No. of participants
(studies)
RR (95% CI)
ZOL vs. Control 665 (1 RCT) 1.99 (0.76,
5.25)
ALN vs. Control 2750 (2 RCTs) 0.88 (0.64,
1.22)
RISE vs. Control 2707 (3 RCTs) 0.88 (0.69,
1.12)
Etidronate vs. Control 322 (3 RCTs) 0.40 (0.03,
5.48)
Ibandronate vs. Control
2.5 mg/d & 20 mg
alternatively
2929 (1 RCT) 0.90 (0.69,
1.18)
0.5 mg & 1mg per 3
months
2860 (1 RCT) 1.27 (0.97,
1.66)
PTH vs. Control 2215 (2 RCTs) 1.54 (1.11,
2.13)
56.5 μg/w 578 (1 RCT) 1.80 (1.00,
3.24)
20 μg/d 813 (1 RCT) 1.10 (0.62,
1.95)
40 μg/d 824 (1 RCT) 1.82 (1.07,
3.10)
Denosumab vs. Control 956 (1 RCT) 0.75 (0.44,
1.27)
HRT vs. Control 79 (2 RCTs) 0.53 (0.17,
1.61)




4093 (1 RCT) 1.00 (0.58,
1.74)
RISE vs. Teriparatide 2070 (2 RCT) 0.75 (0.57,
1.00)
HRT vs. Etidronate 35 (1 RCT) 2.83 (0.33,
24.66)
RR Relative Risk, ZOL Zoledronate, ALN Alendronate, RISE Risedronate, PTH
Pamidronate, HRT Hormone replace therapy
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evidence proved no significant difference between iban-
dronate and risedronate in preventing vertebral fracture
(RR, 1.01; 95% CI, 0.78–1.32, p = 0.92; Additional file 4b,
Table 2) and no significant difference was observed be-
tween ibandronate and risedronate in preventing non-
vertebral fracture (RR, 1.12; 95% CI, 0.75–1.66, p = 0.59;
Additional file 3aa, Table 2).
Hormone therapy vs. BPs
Very low quality evidence indicated no significant differ-
ence between HRT and etidronate (RR, 0.63; 95% CI,
0.12–3.32, p = 0.59; Additional file 4c). Moderate quality
evidence indicated teriparatide (20 μg/week) showed a
significantly superior effect on preventing vertebral frac-
ture and non-vertebral fracture than risedronate (verte-
bral fracture: RR, 1.98; 95% CI, 1.44–2.7, p < 0.0001;
Additional file 4d), without significantly increasing ratio
of discontinuation (RR, 0.75; 95% CI, 0.57–1.00, p = 0.05;
Table 3, Additional file 3bb). No significant difference in
effects of non-vertebral fracture was observed (RR, 1.28;
95% CI, 0.94–1.73, p = 0.12; Additional file 3cc).
Monoclonal antibody medication vs. BPs
Low quality evidence proved the difference between the
effects of alendronate and denosumab on preventing
vertebral fracture was not significant (RR, 0.69; 95% CI,
0.41–1.17, p = 0.17; Additional file 4e). Moderate quality
evidence proved romosozumab had significantly better
effect on preventing secondary vertebral fracture than
alendronate (RR, 0.64, 95% CI, 0.49–0.84, p = 0.001;
Additional file 4f).
Difference between the effects of alendronate and
denosumab on preventing non-vertebral fracture was
not statistically different (RR, 1.49; 95% CI, 0.52–4.24;
p = 0.46; Additional file 3dd), neither was between romo-
sozumab and alendronate (RR, 0.74; 95% CI, 0.54–1.00,
p = 0.05; Additional file 3ee).
Discussion
In this study, we focused on osteoporosis patients with a
history of OVCF. We collected related RCTs, synthe-
sized their results, and finally estimated the secondary
prevention effects of the medications on OVCF. We
found zoledronate, alendronate, risedronate, etidronate,
ibandronate, minodronate, pamidronate, PTH, denosu-
mab, romosozumab and SERMs had significant second-
ary prevention effect on OVCF. In the comparisons
between the medications, teriparatide had a significantly
superior effect to risedronate, and the quality of evidence
was high. The effects of risedronate, ibandronate, PTH,
and SERMs were supported by moderate quality evi-
dence and the effects of alendronate, denosumab were
supported by high quality evidence.
In the result of discontinuation due to adverse events,
PTH was the only intervention that significantly elevated
the ratio. None of the bisphosphonates increased the risk
of GI complaints. Zoledronate, risedronate, and PTH
had significant effect on preventing non-vertebral frac-
ture in patients with prevalent OVCF.
Fig. 3 Forest plot of the secondary prevention effects of: a Parathyroid; b Denosumab; c Raloxifene; and d Bazedoxifene
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Most of widely used BPs, include zoledronate, alendro-
nate, risedronate, etidronate and ibandronate, had sig-
nificant effect, which were supported by moderate
quality evidences. Among the medications, risedronate
and ALN are first line osteoporosis medications, whose
effects have been proved by substantial evidence [5, 7].
Ibandronate is a nitrogen-containing BPs and IV injec-
tion of it allows for a dosing interval even longer than 2
months [59]. Zoledronate is another nitrogen-containing
BPs that has the highest potency among clinical use BPs
[60]. According to our result, 5 mg/year iv injection of
zoledronate could significantly reduce the risk of sec-
ondary OVCF. The extremely low medication frequency
could be its another advantage that might improve
patients’ compliance rate. Significantly elevated adverse
events ratio or rare adverse events caused by BPs (e.g.
osteonecrosis of jaw or atypical fracture, etc.) was not
7reported in any trial. Insignificant difference in GI com-
plaints between BPs and control group indicated prop-
erly administrated BPs might help avoiding the risk of
GI complaints, which was consistent with previous stud-
ies [61].
PTH is a bone anabolic medication that has significant
efficacy against OVCF [62]. In this study, moderate qual-
ity evidence proved that the injection of PTH or teri-
paratide significantly reduce the risk of secondary OVCF
and even the lowest dosage (28.2 μg/week) showed a sig-
nificant effect. Compare with risedronate, teriparatide
showed significantly better effect, which indicated PTH
might have better effect on preventing secondary OVCF.
It was consistent with previous studies that proved PTH
had better effect on spine BMD compare with bisphos-
phonate [63, 64]. But on the other side, the superiority
of PTH over bisphosphonate on hip BMD remains con-
troversial, and it has been showed the PTH had inferior
effect on BMD of distal radius [63, 64]. .Also, PTH treat-
ment was the only medication that was associated with a
series of adverse events that increased the risk of discon-
tinuation. The most frequent adverse event was nausea,
and other complaints included vomiting, headache, diz-
ziness, and leg cramps [43, 46].
SERMs included in the study were raloxifene and
bazedoxifene. Both showed a significant effect in pre-
venting secondary fracture. Raloxifene seemed to have a
better effect when prescribed at a higher dosage, which
was indicated by the significant and substantial hetero-
geneity between the two groups. Besides beneficial skel-
etal effects, SERMs reduce the risk of breast cancer [65].
However, an elevated risk of venous thromboembolic
events due to raloxifene and bazedoxifene has been de-
scribed [52]. Additionally, raloxifene significantly raises
the risk of discontinuation [50]. Therefore, SERMs
should be prescribed with an awareness of their risk of
side effects.
Denosumab is a RANKL inhibitor that was proved to
possess significant effect on preventing secondary
OVCF. Side effects of it include skin rashes, infections,
and osteonecrosis of the jaw [62], but presently, there
was no significant difference in adverse events compared
with control group. Additionally, Boonen et al. reported
a significant reduction of fatal adverse events ratio with
denosumab in patients with prevalent vertebral fracture
[49]. One advantage of denosumab is its low dosing fre-
quency, which might elevate compliance. Romosozumab
is a sclerostin inhibitor that has been proved to have bet-
ter effect on preventing secondary OVCF than alendro-
nate. However, it should be noticed that the cardiac
ischemic events and cerebrovascular events ratio were
higher in romosozumab group. The role of sclerostin in
vessels remains unclear, and the results from basic stud-
ies were controversial [66–68]. Therefore, further evalu-
ation of safety profile of romosozumab is needed.
Unlike the superior effects on OVCF of most medica-
tions, only zoledronate, risedronate, and PTH had a sig-
nificant effect on preventing non-vertebral fractures in
patients with prevalent OVCF. Combined with the effects
of medications on OVCF, the findings might indicate zole-
dronate, risedronate, and PTH might be better options for
patients with prevalent OVCF. Additionally, denosumab
and alendronate showed marginally significant effects.
The results might have less credibility than the main
outcome because of missed information concerning the
non-vertebral fracture status of the participants. But, the
patients included in this study could still be considered as
having a high risk of non-vertebral fracture because preva-
lent vertebral fracture and low bone mineral density are
potential risk factors of non-vertebral fractures [69, 70].
Therefore, the data might be instructive for clinical usage
of the medications.
It must be noted that many phase 3 studies were ex-
cluded from this meta-analysis because the data of pa-
tients with prevalent fractures were not reported. The
exclusion might cause an underestimation of the effects
of some newly developed medications like denosumab
and zoledronate. One limitation of this study include the
absence of searching the gray literature, which might in-
crease the risk of publication bias that might lead to an
overestimation of the effect of newly developed medica-
tions like romosozumab and bazedoxifene. Also, we only
included English written manuscript in this study.
Though no solid evidence showed a bias caused by the
language restriction [71–73], the manuscript written in
other languages should be included in further studies for
a more comprehensive understanding of the effects of
the medications. The generalizability of results of GI
complaints was limited, because most of the trials ex-
cluded patients with upper GI disease at baseline. Add-
itionally, our criteria for assessing the risk of bias might
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be too stringent, which might underestimate the quality
of evidence. Also, it should be noticed that the most
common domains that downregulated the GRADE was
the study limitation and imprecision. The same scenario
has been reported in a review of systematic reviews, in
which the authors indicated the need of high quality
RCTs with large sample size for better clinical decisions
[74]. In the aspect of study limitation, the two main cat-
egories of risk of bias that were rated as unclear to high
risk of bias were performance bias and selection bias.
For a higher quality of evidence, the report of study
might better follow the guidance, like the CONSORT,
and report the procedure of randomization and blinding
could be great help. To decrease the impact from impre-
cision, RCTs with higher sample sizes were needed.
Also, a report of a subgroup of population with preva-
lent fracture would help in expanding the sample size.
Most systematic reviews and meta-analyses included
osteoporosis patients, regardless their fracture history
that introduces indirectness in the results [5–10]. The
results might be overestimated on patients had fracture
history, and for optimized treatment, accurate analyses
of OVCF patients is urged. However, only one system-
atic review satisfied the demand [11]. Compared with
that, we included 14 more RCTs and new medicines
such as romosozumab and abaloparatide that allowed
for a more comprehensive review and comparisons be-
tween different medications. Also, our results included
vertebral fracture, non-vertebral fracture, GI complaints
of BPs and discontinuation due to AEs. In the end, we
evaluated the quality of evidence. The updated informa-
tion could offer more practical evidence for clinical use.
Our results are consistent with those from other sys-
tematic reviews about primary prevention of OVCF [5–
7, 9, 75–77]. This could indicate that the medications
have a consistent effect on osteoporosis patients, regard-
less their OVCF history. Also, medications used to pre-
vent osteoporotic fracture had a low risk of severe
adverse events in most of the 2–3 years follow-ups.
Therefore, the benefits from reducing the risk of frac-
ture, disability, and mortality very likely outweigh the
disadvantages. But, careful evaluation of risk factors and
arrangement of drug holidays are also necessary to
minimize the risk of adverse events [78].
Lack of RCTs that compared interventions of secondary
prevention effect limited our assessment of differences be-
tween interventions. Although indirect comparisons could
be conducted through statistical analyses, high quality
RCTs that provide direct evidence are necessary for a solid
conclusion.
Conclusion
High to moderate quality evidence proved zoledronate,
alendronate, risedronate, etidronate, ibandronate, PTH,
denosumab and SERMs have significant effect on pre-
venting secondary OVCF. Among them, zoledronate,
risedronate and PTH also had significant effects on pre-
venting non-vertebra fracture. Moderate quality evidence
proved romosozumab had better effect than alendronate.
High quality evidence proved that PTH had superior ef-
fect to risedronate, but that medication should be pre-
scribed with caution because of its significantly higher
risk of adverse events.
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